Anti CLEC2D-TLR9 antibody conjugate(Immunitas Therapeutics)

N/A

Report date: 2024/01/03 16:29:50

Base Information

Drug NameAnti CLEC2D-TLR9 antibody conjugate(Immunitas Therapeutics)
Drug Alias NameCLEC2D-TLR9 Myeloid & B Cell Modulator therapy(Immunitas Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionToll like receptor 9 modulators
TargetsToll like receptor 9
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesImmunitas Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmunitas Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A